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INTRODUCTION 
Since the outbreak of HIV/AIDS in the United States in the early 1980s, Congress has 
extended in-kind treatment benefits to HIV-positive persons under Medicaid and, more 
recently, Medicare AIDS Drug Assistance Programs (ADAPs). People who do become 
infected and who cannot afford care eventually receive antiretroviral (ARV) therapy funded 
by Federal and state public health insurance; however, Medicaid imposes an eligibility 
requirement mandating a demonstration of “severely disability” as a condition for receiving 
AIDS treatment.  Medicaid (and Medicare) eligibility requirements restrict benefits to HIV-
positive individuals who are completely incapacitated while access is deferred for those 
struggling in the interim before severe disability.  De facto, HIV-positive Medicaid recipients 
– low-income sufferers and the majority of infected persons of color –experience shorter life 
expectancies and lower qualities of life than their privately-insured counterparts.   
Unfortunately, the story of Medicaid coverage for HIV/AIDS among low-income 
populations in the United States is representative of Medicaid coverage for many other 
“disabling conditions.”  That this paper undertakes to demonstrate the substantial potential 
gains to expanding access to early treatment for HIV symptoms should not be read as a 
“singling out” of HIV/AIDS to the exclusion of those illnesses also undercovered by public 
insurance programs.  On the contrary, this evaluation offers Medicaid assistance for early 
HIV/AIDS treatment as a case study in reform of the status quo administration of Federal and 
state health systems and undertakes to provide a compelling case for early care to low-income 
individuals with health needs. 
Interventions addressing HIV-related illness among poor populations may also address 
an underlying cause of their low earnings, removing a barrier to work and encouraging 
employment by improving physical and emotional capacities as well as future life prospects.  
In particular, single mothers without access to health care and children of HIV-positive 
parents may benefit most from early ARV therapy through increased earnings.  
Recommendations include: (1) raising the clinical threshold for care to enroll HIV-positive 
individuals in the “interim” before severe disability in early drug therapy and (2) raising the 
eligibility threshold for earnings to include those earning at or below 250 percent of the 
Federal poverty line.  Strategies for prevention outreach to disadvantaged populations of color 
and a discussion of macro (Federal- and state-level) and micro (individual-level) fiscal 
projections will locate these recommendations in the context of contemporary shifts in HIV 
infection and careful considerations of cost-effectiveness. 
 
 
OVERVIEW OF FEDERAL HIV/AIDS LEGISLATION 
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Medicaid Eligibility  
 Antiretroviral therapy for HIV is recommended for all patients whose CD4 cell counts 
have dropped below 350 per mL, yet Medicaid-insured HIV-positive persons must wait to 
develop incapacitating physical symptoms before receiving treatment, though they meet 
clinical criteria for drug therapy.1 2 3  This population is not enrolled in treatment at critical 
stages in the progression of its viral load toward full-blown AIDS because eligibility for 
Federal- and state-funded care requires that symptoms be “severe enough” to jeopardize one’s 
capacity to work and to be self-sufficient.4  To qualify for Medicaid or Supplemental Security 
Income, an HIV-infected person must be no longer able to earn at least $700 per month as a 
result of disease complications.5  Thus people in the early stages of HIV, for whom early 
treatment clinically predicts the postponement of AIDS disability, “face the catch-22 of having 
eligibility [deferred] until they become disabled”.6 
 For persons whose HIV status has developed into full-blown AIDS (the fatal, final 
manifestation of HIV infection), Medicaid is the catch-all for end-of-the-line care.  Medicaid 
covers 50 percent of all people and 90 percent of all children in the United States living will 
AIDS.  The majority of HIV-infected people qualify for Medicaid several years after 
becoming infected because they are both poor and incapacitated; 70 percent of those eligible 
meet the criteria of being low-income and permanently disabled.7  An estimated 200,000 to 
240,000 persons with AIDS are covered by Medicaid8. 
Since the 1990s, overall Federal and state spending on Medicaid-covered HIV/AIDS 
treatments has grown steadily in proportion to rising numbers of positive diagnoses, from $3 
billion to $4.1 billion in 2000,9 while Medicaid expenditures on antiretroviral drugs almost 
tripled between 1996 and 1999 alone – increasing from $68 million to $160 million, 
representing the largest increase in ARV expenditures in the period since 1984.10  Total 
Federal spending on HIV/AIDS has grown enormously, and the FY2010 budget includes 
$25.9 billion for HIV programs (See Figures 1 and 2).11 Funding for Medicaid-covered ARV 
therapy has grown incrementally with reported infection rates, yet there has emerged a 
substantial cause for concern.  What appears to show a decline in the rate of new infections 
may in reality describe a demographic shift in prevalence: previously, young, white                                                         
1 Shapiro, M.F., et al. “Variations in the care of HIV-infected adults in the United States: results from the HIV 
Cost and Services Utilization Study.” Journal of the American Medical Association , 281, 1999: 2305-2315. 
2 Levi, Jeffrey and Jennifer Kates. “HIV: Challenging the Health Care  
Delivery System”. American Journal of Public Health, Vol. 90, No. 7, July 2000: 1033-1036. 
3 Kahn, James G, Brian Haile, Jennifer Kates, and Sophia Chang. “Health and Federal Budgetary Effects of 
Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid”.American Journal of Public 
Health, Vol. 91,No. 9, September 2001: 1464-1473. 
4 SSI for People Living with HIV/AIDS 2009: http://www.ssa.gov/pubs/10019.html 
5 Graydon, T. Randolph. “Medicaid and the HIV/AIDS Epidemic in the United States”. Health Care Financing 
Review, Fall 2000: 1. 
6 Kahn et al., ibid. 
7 Kaiser Family Foundation, “U.S. Federal Funding for HIV/AIDS: The President’s FY 2010 Budget Request”, 
May 2009. 
8 Fleishman, et al. 2005. 
9 Health Care Financing Administration, Office of the Actuary:Data from the Medicare and  
  Medicaid Cist Estimates Group, 2000.  
10 Ibid, 1997 (numbers for 1999 projected and confirmed). 
11 Kaiser Family Foundation, 2009, ibid: 1. 
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homosexual-practicing men comprised the highest proportion of infected individuals; now, 
black women and homosexual-practicing black males are at the center of the epidemic.  As is 
discussed further below, these populations are “disconnected” from treatment services and are 
less likely to receive ARV therapy than whites, possibly accounting for the halt in the rise of 
outlays for treatment.  
Despite the enormous increase in funding for HIV/AIDS-related programs, the 
majority of these increases continue to be “discretionary” – i.e., allocated to prevention and 
education efforts both within the United States and globally.12  Changes in Medicaid 
regulations have made meeting the requirements for receiving antiretroviral drugs 
increasingly difficult: In 1996, new welfare restrictions implemented under the Personal 
Responsibility and Work Opportunity Act (PRWORA) also limited the access to Medicaid for 
certain groups at-risk of HIV infection: women transitioned from “welfare to work” under the 
new Temporary Assistance to Needy Families (TANF) program lost the Medicaid coverage 
that was part of a pre-1996 Aid to Dependent Families with Children (AFDC) assistance 
package; regulations removing substance abuse as a disabling condition excluded injecting 
drug users from receiving HIV treatment by virtue of their addiction.13  Both of these 
populations find themselves at high risk, though recent rises in the infection rates of low-
income women of color coupled with exclusion from access to Medicaid-funded early 
treatment and health-related attention that may identify HIV infection itself or drops in CD4 
cell count could predict declines in life expectancy and health measures for low-income single 
mothers without health insurance. 
Medicare Coverage of HIV/AIDS 
The passage of Medicare Part D in 2006 brought substantial changes in coverage to 
the lives of many HIV-positive individuals previously covered by Medicaid.  One quarter of 
the HIV-infected Medicaid-eligible population – 50,000 to 60,000 people – were transferred 
to Medicare Part D, ex-President Bush’s prescription drug plan.14  Demographics again 
account for part of this shift: low-income homosexual-practicing men who were infect in the 
early 1980’s have recently become “elderly” and eligible for Medicare drug coverage, though 
barriers to receiving drug assistance are differentially strict with respect to Medicaid 
coverage: harsher formulas determine need and increasingly complicated applications mediate 
access drug regimens.15  HIV-positive people under 65 may also qualify to receive Medicare 
benefits if (1) “they are deemed disabled due to a physical or mental impairment that prevents 
them from working for a year or more or that is expected to result in death” and (2) “they 
have earned enough work credits to receive SSDI [Social Security Disability Insurance] 
payments … [after] a 5-month waiting period after becoming disabled before receipt of SSDI 
benefits and then a 24-month waiting period before an SSDI beneficiary can receive Medicare 
                                                        
12 Alagiri, Priya, Todd Summers, and Jennifer Kates. “U.S. Spending on Flobal HIV/AIDS, Global Spending on 
HIV/AIDS in Resource-Poor Settings”. Kaiser Family Foundation, July 2002. 
13 Levi and Kates, ibid: 1034. 
14 Piper Report 2005. “Prescription Drug Coverage for HIV/AIDS: State ADAPs, Medicaid, and Medicare Part 
D”: http://www.piperreport.com/archives/2005/05/prescription_dr_2.html 
15 Ibid. 
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coverage, resulting in a total of 29 months before receipt of health benefits through Medicare 
for SSDI recipients.”16 
At present, the Centers for Medicare and Medicaid Services estimate that Medicare 
costs for HIV/AIDS drug therapy exceeds Medicaid costs, through Medicaid remains the 
“gateway” to receiving coverage as those who qualify for Medicare drug assistance become 
eligible, first, by being identified as “severely disabled” by Medicaid criteria and, second, as 
“in need” of a specific drug regimen by Part D according to the standards described above for 
possessing an “impairment exceeding one year” and having waited the necessary 29 months.17  
Equivalent disability restrictions apply for those who pass directly Medicare without being 
assessed for Medicaid eligibility.   
The percentage of HIV-positive people who are covered by Medicaid and Medicare 
has not changed much since 1990.  In 1990, 40 percent of HIV-infected people were covered 
by Medicaid18; by 1996, this figure had risen to 44 percent19.  In 2008, this number has not 
changed.20  Dual coverage under Medicaid and Medicare varies at the state level, yet the 
proportion of those covered under Medicaid consistently comprises the majority of cases for 
those enrolled in some form of public care.21 It is not the magnitude of the “safety net” that is 
at issue – Federal funding of Medicaid and Medicare amounted to $4.1 billion and $4.5 
billion, respectively, in 200822 – but rather the form in which it is extended.  Postponement of 
eligibility until “severe disability,” coupled with the absence of regulatory compensations in 
coverage for rises in “new types” of HIV-infected populations among populations of color 
(discussed below), leave a worrisome delay in need-for-care and access to life-sustaining 
treatment.  
Ryan White CARE Act 
The focus of HIV policy has shifted to prevention.  To complement the substantial 
treatment “safety net,” innovative outreach programs – funded by discretionary outlays - 
emerged in urban centers seriously affected by viral spread in the mid-1990s as aggressive 
prevention efforts.  The Ryan White CARE Act was passed in 1990 to create a flexible source 
of funding for the changing requirements for intervention and treatment among low-income, 
uninsured persons affected by HIV/AIDS.  The Ryan White Act “fills in the gaps” in 
treatment for disconnected HIV sufferers while providing financial support to prevention and 
education campaigns targeted to at-risk populations23; funding or the Act has grown since 
1990 as focus has shifted away from a Medicaid-based support system (see Figure 3).  State- 
and city-level AIDS Drug Assistance Programs (ADAPs) seek greater flexibility in provision                                                         
16 Kaiser Family Foundation. HIV/AIDS Fact Sheet. October 2006. 
17 OMB, CMS Office of the Actuary, HHS Office of Budget, 2008. 
18 Kozak, L.J., E. McCarthy, and M. Moien. “Patterns of hospital use by patients with diagnoses related to HIV 
infection”. Public Health Rep., 1993 Sep–Oct; 108(5): 571–581. 
19 Kaiser Family Foundation, October 2006, ibid. 
20 Chang, Debbie I. “The Current Landscape”. Kaiser Family Foundation. Medicaid Congress, presentation, July 
1, 2009. 
21 Kaiser Family Foundation, October 2006, ibid. 
22 Kaiser Family Foundation. Fact Sheet: U.S. Federal Funding for HIV/AIDS: The FY 2009 Budget    
   Request; April 2008. 
23 United States Department of Health and Human Services, Health Resources and Services Administration 
2009: http://hab.hrsa.gov/aboutus.htm 
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of services to HIV-infected populations and HIV-affected geographic regions, most 
commonly high poverty urban centers like Detroit, Chicago, Los Angeles, and New York 
City. 
Under Ryan White, the Federal government subsidizes states and private non-
governmental organizations in efforts to reach those HIV/AIDS sufferers not enrolled in 
Medicaid and to promote awareness about the virus in affected communities.  It is difficult to 
estimate the number of persons “covered under” Ryan White because prevention efforts, for 
example, extend to those already infect and in treatment as well as those who may pick up a 
provider’s pamphlet.  However, states may “clientize” the Ryan White funds they receive to 
target services to HIV-positive individuals.  In 2007, the State of North Carolina reviewed its 
services to Ryan White aid recipients and found that 7,891 patients were provided direct 
assistance, most often in the form of medical care.24 Funding for Ryan White in FY2008 
amounted to $2.2 billion, which was divided among states and then subdivided among 
programs dedicated not only to treatment but also to vaccine research, advertisements, 
education programs, and evaluations of current programs (see Figure 4 for North Carolina’s 
list of services).25   
The Ryan White CARE Act does not invest in extending early treatment services to 
HIV sufferers but seeks to “connect” them to medical care centers once they have neared 
Medicaid eligibility.  The “steering function” of Ryan White programs means that initiatives 
more often explore the effects of cultural stigma on an individual’s life with HIV/AIDS26 
instead of addressing the gap in infection and access to treatment, with ambiguous 
implications for the HIV epidemic. When Ryan White-funded ADAPs do occasionally 
attempt to provide early drug access to patients, assignment of treatment is often ad hoc and 
scaled to community need – i.e., only the most needy may receive care; those making 
decisions about treatment must allocate Medicaid and Ryan White dollars to cover everyone 
in need, and more often than not funds are “woefully inadequate.”27 28  The laudable 
“stopgap” functions have been under increasing stress as the “demands on Ryan White 
funding have increased” to meet the needs of those who are uninsured, requiring treatment, 
but not yet severely incapacitated by AIDS.29  
In the end, funds are zero-sum: spending on ARV therapy for low-income HIV-
positive individuals who will eventually end up on Medicaid may seem like a poor investment 
compared to the possible gains to community prevention efforts or the equally necessary 
attention to “steering” recently-eligible people into care.  However, the allocation of funds 
and energy to stigma and education effectually universalizes an encounter with “interim” 
disability for low-income uninsured HIV-positive people. 
 
                                                        
24 N.C. Epidemiologic Profile for HIV/STD Prevention and Care Planning (10/08) Chapter 7: RYAN WHITE 
HIV/AIDS CARE ACT AND OTHER SERVICE CONSIDERATIONS, 2008. 
25 HRSA, ibid. 
26 Millbourne, Hank. AIDS Partnership of Detroit. Personal Communication, Spring 2009. 
27 Cordero 2004: http://www.thebody.com/content/money/art14544.html 
28 Levi and Kates, ibid: 1035. 
29 Graydon, ibid: 120. 
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MEDICAID AND LIVING WITH HIV/AIDS 
Medicaid Coverage for Disabling Conditions 
 The limitedness of Medicaid coverage for HIV/AIDS is not unique to the virus and its 
health effects; rather, “interim” illness and deferral of treatment until severe disability is 
symptomatic of most Medicaid services to low-income persons suffering from ailments.  A 
2008 study by Andrew B. Bindman, et al., finds that state requirements to demonstrate 
Medicaid eligibility itself caused 62 percent of Medicaid recipients to experience an 
interruption in care that predicts a higher risk of hospitalization for heart failure, diabetes, and 
chronic obstructive pulmonary disease.30  Persons living in poverty experience higher 
probability of hospitalization: those respondents receiving Temporary Assistance to Needy 
Families are found to be at a “hazard risk” more than two times the risk of the general 
population of Medicaid beneficiaries surveyed.   
  
 The issue is not that Congress is not allocating enough to diseases affecting low-
income individuals who may qualify for Medicaid but that eligibility requirements prevent 
individuals in need from accessing vital care.  While the “necessity” of care ultimately 
resolves itself as a clinical question, the health-related disadvantages of living at, below, or 
near the poverty line for sick persons offers a compelling case for reassessing the way in 
which access to care is presently extended.   
  
 Why HIV/AIDS?  The focus of this paper on HIV seropositivity, the gains to early 
treatment, and the cost-effectiveness of eligibility expansion (discussed below) does not 
deprioritize the needs of HIV-negative Medicaid recipients suffering from other diseases but 
seeks to offer a particularized evaluation in the vein of what should, ideally, form part of a 
broader program of public health insurance reforms. 
 
 Limitations of Medicaid Coverage for HIV-Infected Persons 
Medicaid remains the primary care program for low-income HIV-infected persons; 
indeed, because the majority HIV-positive people are low-income (see footnote 7), Medicaid 
is the primary provider for all persons living with AIDS in the United States.31  Despite its 
inclusiveness for those whose viral load has progressed to full-blown AIDS, an HIV Cost and 
Services Utilization Study, beginning in 1996, found that HIV-infected persons enrolled in 
Medicaid fared worse (compared to privately-insured persons) in a nationally representative 
sample on six measures determinate of general health and access to basic HIV/AIDS 
treatment: 
 (1) fewer than two office or outpatient visits in 6 months 
 (2) emergency department visit without an associated hospitalization in 6 months 
 (3) hospitalization in 6 months 
                                                        
30 Bindman, Andrew B., Arpita Chattopadhyay, and Glenna M. Auerback. “Interruptions in Medicaid Coverage 
and Risk for Hospitalization for Ambulatory Care–Sensitive Conditions”. Annals of Internal Medicine, 
2008;149:854-860. 
31 Kahn, ibid. 
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(4) did not receive PI or NNRTI32 therapy by December 31, 1996 if    
      recommendations for treatment were met 
 (5) never received antiretroviral treatment 
(6) did not receive prophylaxis in the last 6 months for pneumocystis carinii, a type  
      of pneumonia to which persons with AIDS are susceptible, if CD4 count was  
      less than 200.33 34 
 
Measures (4) – (6) demonstrate the comparative inaccessibility of ARV treatment to 
Medicaid beneficiaries.  Measures (1) – (3) indicate that HIV-infected persons on Medicaid 
are generally sicker than those on private insurance plans – they are more likely to visit a 
doctor, emergency room, or hospital for HIV-related complications.  The disparity between 
public-funded and private-funded HIV health care is a statistical function of eligibility 
criteria: fewer HIV-infected Medicaid beneficiaries were receiving treatment compared to 
HIV-infected non-beneficiaries because the progression of their disease did not yet qualify 
them for ARV regimens.  That Medicaid recipients are also, on average, more prone to 
hospitalization indicates that beneficiaries experience more negative health shocks by virtue 
of their exclusion from early treatment.  Moreover, because all those identified as “HIV-
infected Medicaid beneficiaries” by HCSUS include also those already receiving ARV drug 
regimens through Medicaid, these findings additionally indicate that Medicaid-funded AIDS 
care for eligible recipients is inferior to private care.  While qualitative disparity in 
public/private care exists for almost all disease treatments, the HCSUS’s finding 
demonstrating a lower probability of having ever received ARV therapy among AIDS 
sufferers is an is particularly troubling.  This data indicates that low-income people diagnosed 
with full-blown AIDS are having their treatment deferred or that (as Bindman’s more general 
finding indicate) eligibility requirements interrupt the process through which drug regimens 
are obtained. 
  
Medicaid has become an option of last resort in two senses: (1) for those whose HIV 
symptoms have finally qualified for benefits, and (2) for those unable to access private care 
that meets the clinical standards for appropriate quality.  Comparisons of the health of HIV-
positive, privately-insured persons and that of publicly-insured HIV-positive persons reveals 
that the “sicker” one gets the more likely a person is to be covered by Medicaid than a private 
insurance plan.  In a 2003 followup study to the HCSUS survey Dana Goldman, et al., 
investigated 
 
“the impact of disease severity on insurance coverage, the investigators used 
HCSUS data to develop a model to adjust for factors (for example, race, sex, 
HIV exposure route, education, time since diagnosis, and lowest CD4 
lymphocyte count) that might affect insurance outcomes. Their findings 
indicate that the probability of having private insurance falls gradually from 
about 0.37 with a CD4 count of 700 (the normal count for healthy people is 
usually 600-1200) to 0.23 as lowest CD4 count approaches zero. On the other                                                         
32 Classes of ARVs: protease inhibitors (PIs) or non-nucleoside reverse transciptase inhibitors (NNRTIs). 
33 CD4 cell counts measure immune system health.  Mean levels for healthy individuals are between 800-1050 
per mL. 
34 HIV Cost and Services Utilization Study (HCSUS): Agency for Healthcare Research and Quality (AHRQ) and 
RAND, 1996-1998. 
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hand, the probability of having public insurance rises dramatically from 0.36 to 
0.67.”35 
 
A rule emerges in these analyses: low-income people living with HIV must wait until 
their symptoms become “so severe that they are disabled”36.  The qualification of disability is 
linked explicitly to earnings, and the level at which it is set ($700/month) makes it 
paradoxically impossible for poor HIV-infected persons to pay for their own care in the 
interim.  The de facto result is a system by which Medicaid coverage is withheld until an 
AIDS sufferer is no longer able to support herself/himself, with “self-sufficiency” being 
defined as earning an annual income of at least $8,400 ($700/month) – a standard $2,430 
below the official poverty threshold for a single earner, or (e.g.) for single mothers, $6,170 
(one child) and $9,910 (two children) below the poverty line. 37  For HIV-infected persons 
living at, marginally above, or below the poverty line, there exists no real support for early 
treatment, though HCSUS demonstrates its potential for preventing unexpected 
hospitalizations (and their associated costs) and despite the illogicalness of waiting until an 
AIDS sufferer’s income drops far below the poverty line before addressing the cause of 
her/his low earnings. 
  
However, the counterfactual to the current “interim” delay is not immediately clear.  
The effectiveness of reformed interventions offering access to early care will largely depend 
on the efficacy of treatment itself; cost-effectiveness will also be variable to drug prices and 
number of new enrollees such a change would invite into care.  Understanding the particular 
needs of HIV-positive, low-income persons will be essential to the recommendations 
extended below and should be an integral part of all reform efforts directed towards diseases 
affecting Medicaid recipients or potential Medicaid-eligibles. 
  
 The current health needs of the population of low-income, HIV-positive persons are 
directly related to the present gap in treatment.  A 2000 study by Katz et al. evaluated the 
needs of a nationally-representative sample of HIV-infected persons, those receiving 
Medicaid or Medicare assistance, those on private insurance plans, and those whose care was 
covered under the Ryan White CARE Act.  Respondents were asked to self-identify with five 
unmet needs: (1) income assistance or health care benefits (benefits advocacy), (2) a place to 
live (housing), (3) home health care, (4) mental health or emotional counseling (emotional 
counseling), and (5) drug or alcohol treatment (substance abuse counseling).  Sixty-seven 
percent of respondents possessed at least one unmet need, and 34.6% lacked necessary 
income assistance or health care benefits (benefits advocacy need), with declining 
requirements for each need included in the list above.  Most startlingly, only 60.3% of the 
sample had contact with a case manager in the past 6 months, meaning that only this 
percentage of HIV-positive adults were connected with a medical professional who was 
monitoring their health. (see Figure 3)38  Some variability was found across states as is                                                         
35 Goldman, D.P., Leibowitz, A.A., Joyce, G.F., and others (2003). "Insurance status of HIV-infected adults in 
the post-HAART era: Evidence from the United States." Applied Economics and Health Policy 2(2), pp. 85-91. 
http://www.ahrq.gov/research/jan04/0104ra24.htm 
36 Levi and Kates, ibid: 1034. 
37 Federal Register, Vol. 74, No. 14, January 23, 2009: 4199–4201. 
38 Katz, Mitchell H., et al. “Prevalence and Predictors of Unmet Need for Supportive Services Among HIV-
lnfected Persons: Impact of Case Management”. MEDICAL CARE, Volume 38, Number 1, pp 58-69, 2000: 60, 
This paper is published in its original version  
Gabriel Tourek. Expanding Medicaid Coverage…  icops2010 9  
common to Medicaid coverage in general.  However, the nature of Ryan White funding, 
which is allocated based on perceived need, means that states with large, urban-based HIV 
epidemics receive more aid and show greater coordination among HIV-related interventions 
while states with rural populations of HIV-positive people are often particularly deprived of 
any meaningful care system. 
 
Disproportionate Disadvantage for HIV-Infected Persons of Color 
Disconnection is a serious problem for African American communities.  HIV/AIDS 
infection rates have reached epidemic proportions among African American men and women.  
Urban populations of black men who have sex with men (MSM) have HIV prevalence rates 
between 24.2 and 37.8 percent39; young black MSM aged 13-19 have seen their incidence of 
infection double since 2004 within the urban areas40 - a rate more than twice that of white 
MSM41. Hank Millbourne, Director of the AIDS Partnership of Detroit, asserts that 
“behaviors are just not lining up with knowledge about the disease”42, and young black men 
are getting infected and avoiding much-needed treatment out of fear of stigma and exorbitant 
costs.  Additionally, women of color living in areas of low socioeconomic status also find 
themselves the victims of a colluding combination of infection risks: high incarceration rates 
that deplete the pool of available males, sex for survival, and fluid sexual networks are 
prevalent in conditions of poverty.  Black men and women nationwide are at “approximately 
ten times” greater risk for HIV infection than whites43.  The racialized impact of HIV/AIDS, 
however, is not new.  HIV prevalence in urban black communities boomed in the early 1990s 
when crack use and sexually transmitted infection rates remained absent from the Center for 
Disease Control’s (CDC) AIDS interventions, creating a breeding ground for sexual 
interactions with high risks of infection44.  Presently, 68 percent of HIV-positive females 
nationwide are African Americans, the majority of whom live below the poverty line.45 
William Julius Wilson’s hypothesis predicting the exponential circulation of “poverty 
ills” in areas of concentrated disadvantage here appears to have a particularly pertinent 
application.  Research suggests linkages between neighborhood factors – or “ecologic 
stressors” – and the rate at which HIV progresses into AIDS.  Aiello, et al., report that 
“concentrated disadvantage, unequal income distribution, residential segregation, and poor 
quality of [one’s] built environment” produce statistically significant, positively associated 
effects for the progression from HIV to AIDS through “stress-related hormonal changes”46.                                                                                                                                                                               
58, 63. 
39 City of Chicago Department of Health, HIV/AIDS Surveillance Unit. “HIV Prevalence and Unrecognized 
HIV Infection Among Men Who Have Sex with Men” 2008. 
40 Prachand, Nikhil. Department of Health, City of Chicago: HIV/AIDS Surveillance Unit. Personal 
Communication, 2/25/09. 
41 Centers for Disease Control. “HIV prevalence, unrecognized infection, and HIV testing among men who have 
sex with men―five US cities, June 2004–April 2005”. MMWR 2005;54:597–601. 
42 Hank Millbourne. Director of AIDS Partnership, Detroit. Personal Interview, 2/20/09. 
43 Centers for Disease Control and Prevention. 2007 HIV/AIDS Surveillance Report. US Department of Health 
and Human Services: Atlanta, Georgia, 2009. 
44 Levenson, Jacob. The Secret Epidemic: The Story of AIDS in Black America. New York: Pantheon, 2004. 
45 Ibid. 
46 Aiello, et al. “Population Levels of Psychological Stress, Herpesvirus Reactivation and HIV”. AIDS BehaviorI. 
2008: 1. 
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In the City of Detroit, 84 percent of people infected between the ages of 13 and 24 are black.47  
While no studies have yet attempted to measure prevalence specific to race within the City of 
Detroit itself (due to complications involving movement to and from the suburbs and the large 
intermixing of the subrurban and urban gay male populations), Richard Lichtenstein, Ph.D., 
compared prevalence for one Eastside zipcode within the city (48213) to prevalence for the 
city as a whole and found that the HIV infection rate has over 10 percent higher (24.92 
percent) than for the city population; this zipcode is almost entirely African American.48   
These findings attest to the influence of environmental factors in HIV-related health 
problems beyond those traditionally-conceived to originate from individual sexual behaviors, 
socioeconomic status, or genetic markers.  Additionally, HIV-positive African Americans and 
Latinos are overall more likely to rely on Medicaid than HIV-positive whites49 50: in 2003, 59 
percent of African Americans with HIV/AIDS relied on Medicaid, compared with 32 percent 
of whites.51 52  Even within Medicaid African American HIV-infected Medicaid beneficiaries 
suffer greater disconnection from services: those eligible for HIV care on average enter 
treatment 8 months later and spend 8% less time on PI or NNRTI therapy than their non-
Hispanic white counterparts.53  Low-income HIV-infected African Americans on average are 
at higher risks for HIV infection and receive lower quality treatment on Medicaid than 
Medicaid recipient, HIV-positive whites.  Addressing these disparities will require focusing 
special efforts on identifying differential racial characteristics attending to community 
composition, culture, and socioeconomic status that uniquely disadvantage this population to 
infection and exclusion from quality care. 
POVERTY, HIV/AIDS, AND MEDICAID 
As noted above, Medicaid eligibility requirements extend benefits only to “severely 
disabled” HIV-infected individuals earning below the poverty line, leaving low-income HIV 
sufferers to fend for themselves or to seek support in the patchwork of programs 
(under)funded by Ryan White outlays.   
Those in the “interim period” before developing severe disability and those newly 
alienated from public care have entered a burgeoning class of HIV-infected persons living 
without any connection to medical assistance: of the 850,000 to 950,000 people living with 
HIV in the United States, between 42% and 59% are estimated to not be in care.54  Rising 
HIV prevalence in areas of concentrated poverty and in limitations to access for at-risk, low-
income populations increasingly make HIV/AIDS a disease of poverty, and Medicaid                                                         
47 Medical News Today. “Blacks, MSM Remain Most Affected by HIV/AIDS”. 2 December 2008. Online: < 
http://www.medicalnewstoday.com/articles/ 131450.php>. 
48 Lichtenstein, Richard. “Racial, Ethnic and Socioeconomic Health Disparities in the US”. (data from 
www.chimart.org) University of Michigan, School of Public Health, presentation, June 2007. 
49 Kaiser Family Foundation. October 2006, ibid. 
50 Kaiser Family Foundation. HIV/AIDS Policy Brief. May 2004. 
51 Fleishman J. January 2002, cited in Ruiz S. African Americans and HIV/AIDS. Fact sheet. Washington, DC: 
Kaiser Family Foundation; 2003. 
52 Ruiz, S. “African Americans and HIV/AIDS: Fact sheet”. Washington, DC: Kaiser Family Foundation; 2003. 
53 Crystal, Stephen, Usha Sambamoorthi, Patrick J. Moynihan, and Elizabeth McSpiritt. “Initiation and 
continuation of newer antiretroviral treatments among medicaid recipients with AIDS”. Journal of General 
Internal Medicine, Vol. 16, No. 12, December 2001: http://www.springerlink.com/content/226322j527 11361j/ 
54 Kaiser Family Foundation. HIV/AIDS Policy Brief. May 2004. 
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eligibility criteria ensure that if individuals are not already poor, they will become poor before 
being able to enroll in treatment. 
What this “waiting game” means for households supported by HIV-infected adults is 
troubling.  In 2000, Shuster et al. estimated that 28% of HIV/AIDS sufferers had one or more 
children living with them; of that group, 75% had previously registered CD4 cell counts 
between 0 and 199 per mL, far below clinically recommended levels, and 30% (included 
within that 75% group) had full-blown AIDS.55  Of all respondents sampled, 83.3% earned 
less than $25,000/year; 56.5% earned less than $10,000/year.  The households – containing 
approximately 100,000 children56 – of low-income HIV-infected parents are likely to 
experience income shocks and rising health care costs as primary earners go without access 
health insurance, and it is not until many of these caregivers become functionally 
incapacitated that Medicaid care will finally be extended.  Maine and Massachusetts57 have 
approved extending early treatment to HIV-infected mothers, but evaluations have yet to be 
conducted regarding the number of new enrollees and effectiveness of treatment.  Moreover, 
income eligibility requirements are set at the poverty line and may not provide for the largely 
unpredictable health needs of those adults earning just above. 
GAINS TO EARLY TREATMENT 
 Life Expectancy and Costs per Life Year Gained 
 Life for HIV-infected, low-income adults in the “interim” is not a life free from health 
problems, nor is deferring ARV therapy lack implications for future treatment outcomes.  
Early treatment for HIV infection can significantly forestall the advent of AIDS and address 
the symptoms of HIV infection as they arise.  Medical advances since the early 1980s have 
“transformed [HIV/AIDS] from a rapidly fatal infection diagnosed at a late stage of the 
disease to a chronic progressive illness that affords many years of productive life under 
complex treatment regimens”.58   
 
 Kahn et al. (2000) modeled the health effects of extending Medicaid to HIV-infected 
persons for early access to antiretroviral therapy.  The study found that if implemented 
nationwide the plan (over 5 years) would enroll 38,000 more HIV patients in Medicaid, 
reduce AIDS diagnoses by 13,000, prevent 2,600 deaths, and 5,816 life years to the 
population of HIV-infected Medicaid beneficiaries.  Over a 10 year period, life year gains are 
projected to increase by a magnitude of five, and the decline in AIDS deaths is expected to 
more than double (see Figure 7).   
 
 Federal costs for each five year period at current eligibility levels are estimated by 
Kahn et al. to be $24.3 billion; expanding early treatment is estimated to cost an additional 
$739 million over five years: Medicaid costs would rise by $1.43 billion, but decreases in 
costs for other programs (state ADAPS and SSI) would offset are projected to offset this                                                         
55 Shuster, et al. “HIV-Infected Parents and Their Children  
in the United States”. American Journal of Public Health, Vol. 90, No. 7, July 2000: 1076-1077. 
56 Ibid: 1076. 
57 AIDS Action Council. Policy Facts: Early Treatment for HIV Act Expanding Care Through Medicaid. June 
2004: http://www.thebody.com/content/art33771.html 
58 Graydon, ibid: 120. 
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rise.59  The cost for quality adjusted life year gained (after five years) would be $879.97.  
Kahn et al. offer two options for Federal budget neutrality: (1) bargain for lower drug prices, 
and (2) transition early treatment recipients back onto employment-based insurance – by 
subsidizing the purchase of “community-rated health insurance (i.e., by paying premiums for 
COBRA [Consolidated Omnibus Budget Reconciliation Act] to continue employment-based 
health coverage or for state high-risk pools)” insurance administration could replace 
inefficient plans that would continue to regulate HIV-positive Medicaid recipients as “high-
risk” despite health improvements.60 61 
 
 A study conducted by Bruce Schackman et al. (2001) used a state-level simulation 
model to estimate life expectancy and quality of life year gains for early antiretroviral 
treatment for HIV-infected persons nearing the CD4 cell count level at which treatment is 
clinically recommended.  Average gains in life expectancy for initiating early treatment at an 
intermediate CD4 level of 500 per mL was 2.08 years (1.98 years when adjusted for quality of 
life).62  Gains to initiated treatment at an early stage in disease progression have yet to be 
evaluated but could offer greater life expectancies and improved quality of life for those 
interim years before full-blown AIDS develops. 
 
Schackman et al. estimate the Federal cost per quality-adjusted life year gained to be 
approximately $17,300, but over a 5 year period total increases in taxpayer cost would 
amount to $11,500 per patient because early treatment would simply require an earlier 
payment of the cost that is deferred at current Medicaid eligibility levels.63 The disparity in 
Kahn’s and Schackman’s measures is explained, first, by Kahn’s discounting of declines in 
costs to state ADAPs and SSI and, second, by Kahn’s assumption of rising Medicaid 
HIV/AIDS costs in the next five years without expansion of early treatment. 
 Quality of Life and Increased Economic Productivity 
  
 For HIV-infected persons earning at the margins of the poverty line, basic 
improvements in health can produce increases in number of hours worked, level of 
productivity, motivation, and future life prospects.  While average gains of 2 years of 
additional life must not be taken out of proportion, at the very least, early treatment will help 
HIV sufferers avoid costly and unpredictable hospitalizations and will offer an opportunity to 
take their health under control.  Goldman et al. (2001) find that providing access to early 
treatment may show the greatest cost-effectiveness through reducing the high costs of 
hospitalizations.64  Adding productive years to the lives of HIV-infected earners can also 
encourage savings and planning for inability to work.  For thousands of children, extending                                                         
59 Kahn, et al., ibid: 1464. 
60 Ibid: 1468. 
61 Ibid: 1464. 
62 Schackman, et al. “Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for  
Uninsured HIV-Infected Adults”. American Journal of Public Health, Vol 91, No. 9, September 2001: 1460. 
63 Ibid: 1460. 
64 Goldman, Dana P., Jay Bhattacharya, Arleen Leibowitz, Geoffrey F. Joyce, Martin F. Shapiro, and Samuel A. 
Bozzette. “The Impact of State Policy on the Cost of HIV Infection”. Medical Care Research and Review, Vol. 
58, No. 1, Mar. 2001: 31-53.  
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the working life of an HIV-infected parent could mean the difference between growing up in 
poverty and not. 
 
The costs of early therapy could also be offset by the contributions to GDP of HIV-
infected workers given several extra years of working life as well as the additional taxes these 
workers may pay.  However, real cost gains accrue to HIV sufferers themselves: the high out-
of-pocket costs of hospitalization, doctor visits, and uninsured health treatment that are 
common occurrences in the “interim” before severe disability put stress on already low 
incomes, and early treatment and coverage for health shocks could offer HIV-positive earners 
reprieve from unpredictable expenditures or burdensome debt to medical providers. 
Cost-Effectiveness 
The Medicaid program functions by making matching Federal funds available to states 
meeting the Congressional standards for provisions of care.  Since 1982, states have 
participated, though there is substantial variation in the generosity of benefits, eligibility 
requirements, and provider payments.65  Only one state, Maine, has extended early access to 
drug therapy, though this change has yet to be evaluated.  Yet it seems that Congressional 
regulation mandating early treatment would impose costs variable to states’ populations of 
HIV-infected persons.   
Kahn’s and Schackman’s conflicting estimates, rather than testifying to the 
indecipherability of early treatment costs, make a case for a more systematic reform to 
Medicaid coverage for eligible HIV/AIDS sufferers.  Bargaining for lower ARV costs should 
be explored: In 2007, Simpson et al. estimated the daily cost of ARV regimens to be between 
$52.75 per day (clinically symptomatic) and $65.55 per day (severely symptomatic) based on 
the 50th and 75th percentile of Medicaid mean drug costs for patients in South Carolina.66  
Annually, ARV costs on average are projected to be between $19,253.75 per patient and 
$29.925.55 per patient.  Medicaid covers these costs currently, and so the question becomes 
regarding the cost of extending ARV therapy earlier to HIV-positive persons.   
In light of current spending, Kahn et al.’s consideration of falling “alternative” 
program costs post-early treatment expansion and the proposals to bargain for reduced drug 
prices and to transition stabilized HIV-positive workers onto employment-based insurance 
present a compelling case for expanding coverage.  Additional costs of $879.97 per additional 
quality adjusted life year gained appears a marginal expense given the potential for increased 
earnings and reduced hospitalization costs.  Though it is difficult to model, tax revenues 
collected from populations of HIV-positive low-income individuals who may not be working 
as much or at all without early treatment could partially offset or even exceed Federal 
investment in their drugs regimens. 
Public health insurance systems in Canada and the United Kingdom do provide early 
access to treatment for HIV-positive persons, though the effectiveness of this care is mediated 
by general characteristics of care provision in each nation.  For example, it is difficult to                                                         
65 Kaiser Family Foundation, May 2004, ibid. 
66 Simpson, Kit N., Walter J. Jones, Rukmini Rajagopalan, and Birgitta Dietz. “Cost Effectiveness of 
Lopinavir/Ritonavir Compared with Atazanavir plus Rit: Methods”. Clin. Drug Invest., 27(7), 2007:443-452. 
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access coverage, in general, for “high cost treatment for chronic or life-threatening diseases 
and conditions for Canadians who are working but have limited or no private insurance,” and 
ARVs are no exception.67  Recommendations for Medicaid coverage reform must inevitably 
be considered in the United States context, and limitations in the ability of other developed 
nation, public insurance system governments suggests the need for a comprehensive approach 
to individual insurance coverage and approaches to the potentially high costs of ARV 
regimens for those who are in need of intensive treatment. 
Prevention Gains, Containment of Epidemic 
For areas of concentrated disadvantage and high HIV prevalence, early antiretroviral 
therapy could address the rising rates of infection among disconnected populations.  HIV-
positive persons in high-poverty centers, substance abuse is often also a problem68, and given 
the spread of HIV through networks of crack cocaine distribution and use in largely African 
American urban communities, comprehensive health care for HIV-positive persons including 
drug and alcohol counseling could remove the enabling conditions for risky sexual behavior 
or unsanitary needle use.  Recent randomized clinical studies evaluate to the effectiveness of 
alcohol and drug treatment in reducing HIV risk behaviors: Chawarski et al. (2007) found 
statistically significant 26 percent reductions in HIV risk behaviors among heroin dependent 
individuals in Muar, Malaysia,69 while an ongoing study (to be completed in 2010) measures 
the HIV risk behaviors of methadone patients (heroin users) in Wuhar, China70. 
Moreover, extending treatment to members of disadvantaged communities of color 
could combat perceptions of alienation among others who are HIV-infected.  Seeing HIV-
positive persons receiving treatment with perceptible gains in life quality and life expectancy 
may encourage others to seek care.  The disproportionately low levels of HIV care enrolment 
among seropositive African Americans (whether due to significant barriers to access or to 
cultural issues) requires attention.  Beyond the possibilities of preventing new infections and 
promoting the attractiveness of car enrolment, early treatment could also connect 
“disconnected” communities of low-income African Americans to medical centers and HIV 
education outlets in a way that promotes greater awareness about HIV/AIDS, sexual safety 
device availability, and knowledge strategies for infection risk aversion.  If there is a cultural 
or informational divide contributing to the epidemic-scale rates of infection among young 
men and women of color in urban settings, linking HIV-positive community members to 
sources of not only treatment but also prevention knowledge and tools could make them 
empowered advocates for prevention and accessible resources for HIV-positive individuals 
curious about treatment options. 
                                                         
67 AIDS Committee of Toronto. Universal Access to HIV/AIDS Treatment, 2007: 
http://www.actoronto.org/home.nsf/pages/act.docs.0765 
68 Katz, ibid. 
69 Chawarski, M.C., M. Mazlanb and R.S. Schottenfeld. “Behavioral drug and HIV risk reduction counseling 
(BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial”. Drug and 
Alcohol Dependence, Volume 94, Issues 1-3, 1 April 2008, Pages 281-284 
70 Haller, Caroly, Marek C. Chawarski, and Wang Zhou. “Behavioral Drug and HIV Risk Reduction Counseling 
in Methadone Patients in China”: http://www.yaletrials.org/clinicalTrials/displayTrial.asp? 
nctID=NCT00757744&trialListing=Y&row=323 
This paper is published in its original version  
Gabriel Tourek. Expanding Medicaid Coverage…  icops2010 15  
RECOMMENDATIONS 
Congress should mandate that HIV-positive persons unable to afford private care be 
provided with early antiretroviral therapy funded by Medicaid: 
(a)  Individuals will be eligible if their CD4 cell counts are 600 per mL or lower and 
will have access to medical case worker evaluations to determine appropriateness of various 
treatment regimens and to monitor the health of patients.  Kitahata et al. (2009) find that 
withholding treatment for CD4 counts of 500 per mL and above increases a patient’s risk of 
death by 94 percent71; because 500 CD4 cells per mL is the standard for evaluating the 
clinical appropriateness of care72, beginning evaluations of need for ARV therapy before this 
level may offer health returns for those patients whose CD4 counts may fluctuate and 
compromise immune systems.   
(b)  Income baselines should be set at 250 percent of the Federal poverty threshold for 
the recipient’s household type to compensate for illness occurring before full-blown AIDS 
that may compromise the earnings of even those with incomes above the poverty line.  Two 
hundred and fifty percent of the Federal poverty line is the current standard for access to 
Medicaid care for persons with cancer living in the State of New York, and the New York 
Department of Health’s assertion that this standard allows individuals to “gain access to life 
saving treatment and services”73 translates informatively as a model for Medicaid coverage 
for HIV-positive, Medicaid eligible persons.  To understand early treatment as a support for 
earnings in the “interim” before severe AIDS-related disability is to conceive of an HIV-
positive earner as economically self-sustaining.  However, current eligibility requirements 
tied to an earnings level below the Federal poverty line does not allow medical support to 
intervene in critical stages of disease progression.  If evaluations for care eligibility begin at 
250 percent of the poverty line, severe income shocks and enforced interim-period poverty 
can be dealt with before they redound not only to the HIV-positive persons immediate 
subsistence, but also his/her future earnings and the prospects for his/her family and children.  
H.R. 3962, the Affordable Health Care for America Act bill recently approved by the U.S. 
House of Representatives, establishes a criteria for Medicaid coverage at 150 percent the 
Federal poverty line74; however, the marginal costs of extending treatment for HIV/AIDS 
(and its attendant costs) at an earlier stage in disease progression simply transfer the bulk of 
expenditures per patient to a period before severe disability.  Per Kahn et al.’s discussion of 
transferring HIV-positive earners onto private, employer-based insurance plans, a higher 
threshold for HIV-positive, low-income persons could oddly keep such “eligible’s” off of 
Medicaid by stabilizing their health and helping them to afford private insurance. 
 (c)  To facilitate the inevitable transition into severe illness and incapacitation for 
low-income, HIV-infected persons, Congress should also fund assistance programs that help 
early treatment recipients to save and plan for the future.  Caseworkers should also be                                                         
71 Kitahata, Mari M., et al. “Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival”. New 
England Journal of Medicine. Volume 360:1815-1826, April 30, 2009, Number 18: 
http://content.nejm.org/cgi/content/full/360/18/1815 
72 Kahn, et al., (ibid) model for CD4 counts below 500 per mL. 
73 New York State Department of Health. Medicaid Cancer Treatment Program: Breast, Cervical, Colorectal and 
Prostate Cancer (MCTP): http://www.health.state.ny.us/nysdoh/bcctp/bcctp.htm 
74 H.R. 3962, Section 1017. 
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assigned to monitor the income status of families supported by an HIV-positive Medicaid-
recipient earner and to coordinate eligibility and access to other means-tested income transfers 
(unemployment insurance, social security/disability insurance) and in-kind benefits (food 
stamps, subsidized child care).  This service would meet the “benefits advocacy” need 
identified by more than one-third of HIV-positive persons and address the lack of access to 
caseworker review reported of 39.7% of this population.75  Though lack of caseworker access 
is a problem for other sick Medicaid recipients, enforcing new standards for care that are tied 
to income level and clinical definitions of treatment need (CD4 counts) may streamline access 
and make contact with caseworkers more readily enforceable. 
 (d)  Congress should also fund investigative inquiries (1) into Medicaid-funded 
HIV/AIDS care provider programs that demonstrate lower quality services compared to 
private providers, and (2) into the gap in Medicaid enrolment in high-poverty African 
American communities with a guarantee that recommendations would be reflected in 
Medicaid eligibility rules and care standards or elsewhere in prevention education and HIV 
outreach program funding. 
 These changes will require Congressional legislation modifying current eligibility 
requirements, for Federal policy requires that expansions in eligibility be budget neutral 
without explicit increases in expenditures allocated to cover increased program costs.76  A 
provision should also be included to link the scope of Medicaid-funded HIV/AIDS coverage 
medical advancements in treatment; as new technologies offer improvements to life 
expectancy and life quality, low-income HIV-infected persons should not be denied the same 
treatment options available to their privately-insured counterparts. 
DISCUSSION OF POLITICAL FEASIBILITY 
The political feasibility of extending Medicaid coverage to include early antiretroviral 
therapy for low-income HIV-infected persons may encounter resistance.  Medicaid recipients 
lack political capital as an interest group: receiving increases in care funding must overcome 
general antipathy to increased welfare spending.  HIV-positive populations in particular face 
stigma that draws on moral and religious justifications.  However, HIV awareness has made 
significant headway since the 1980s, and Congress has proved receptive to considering early 
treatment (as evidenced by its approval of Maine’s early ARV initiative). 
The greatest resistance may focus on the costs of early treatment, but his concern, too, 
may not be convincing given the current political climate.  H.R. 3962 authorizes states to 
early treatment to HIV-positive persons77, among illnesses like cancers (and early detection of 
their growth). Though the Senate has yet to consider this provision, its inclusion reflects the 
receptiveness of Congressional representatives to Medicaid extension to at-risk HIV sufferers 
and an implicit awareness of the unlikelihood of states to take action themselves.  Still, an 
authorization is far from a requirement mandating eligibility reform, though the provision 
may allow for funding leeway in states that choose to follow Maine’s example.  
                                                        
75 Katz, ibid. 
76 Kahn, ibid. 
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Winning mandatory requirements for early treatment will require strong advocacy for 
reform, though generating substantial political will may depend on demonstrating success in 
individual states.  With the possible arrival of more accessible access to publicly-funded 
health care in the United States under the Obama administration, local and state actors should 
pursue funds that may become available to provide early treatment to those suffering in the 
interim period before they become eligible for Medicaid. 
CONCLUSION 
Given the cost-effective gains in life expectancy and quality of life for low-income 
HIV-positive persons of early clinical interventions for HIV-infected individuals, changes in 
Medicaid eligibility may carry substantial implications for the poverty that persists in the 
“interim” period before severe AIDS-related disability.  The partial incapacitation of HIV-
positive earners jeopardizes not only personal health but also the wellbeing of the households 
that are supported by their labor.  Extending additional, productive years of life to low-
income, HIV-positive persons may be the difference between living in poverty and not, with 
attendant implications for quality of life, ability to save, and child development.  Undeniably, 
the status of Medicaid coverage for HIV/AIDS among low-income populations in the United 
States is representative of Medicaid coverage for many other “disabling conditions.”  Though 
this paper “singles out” HIV/AIDS to the exclusion of those other illnesses also undercovered 
by public insurance programs, the case for early treatment for HIV/AIDS is a study in 
dynamic potential that lies in reforming the Medicaid system in a more comprehensive 
fashion.  
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APPENDIX 
 
Figure 1: Figure 1: Federal Spending on HIV/AIDS by Type (Mandatory or Discretionary), 
1981 – 200278  
 
 
 
 
Figure 2: Federal Funding for HIV/AIDS, FY 2006 –FY 2010 (US$ Billions)79 
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Figure 3: Federal Funding for the Ryan White Program, FY 1991–2008 80 
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Figure 4: Services provided to Ryan White Part B clients, 2007 (CAREWare)81 
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Figure 5: HIV Infection by Race/Ethnicity, 200682 
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Figure 6: Weighted Analyses of Need and Unmet Need for Supportive Services83  
 
 
 
Figure 7: Health Outcomes (New AIDS Diagnoses, Deaths, and Life-Years) and Fiscal 
Outcomes for the Current Insurance Mix, With the Medicaid HIV Eligibility Expansion 
Implemented, and the Difference, by Year84 
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Figure 8: Selected Sensitivity Analyses: Expected 5-Year Net Federal Costs for Range in  
Values of Key Model Inputs85 
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